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• Diffuse Large B-Cell Lymphoma (DLBCL) is the most 
common aggressive Non-Hodgkin’s Lymphoma subtype1
• National Comprehensive Cancer Network (NCCN) issues 
peer-reviewed guidelines for DLBCL treatment2
• National Cancer Institute (NCI) publishes Surveillance, 
Epidemiology, and End Results (SEER) statistics for DLBCL3
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• Determine if workup and treatment for DLBCL rendered 
at LVHN was in compliance with NCCN guidelines
• Compare LVHN’s DLBCL population trends to those 
published by the NCI
• Retrospective chart review of 269 DLBCL patients 
identified by LVHN’s Tumor Registry from 2014 to 2018
• Utilized EPIC and Mosaiq to access electronic medical 
records (EMR) to record:
– Demographic information 
– Chemotherapy regimen
– Baseline:
• Lugano staging (I, II, III, IV)
• Viral testing results
• Lactate dehydrogenase measurement
• B symptom presence
• PET scan completion status
• Echocardiogram/MUGA completion status
• Removed 88 patients from initial dataset due to:
– Initial treatment at another hospital – 41 (46.6%)
– Treatment by pediatrics unit – 3 (3.4%)
– Patient declined treatment or entered hospice without 
treatment – 14 (15.9%)
– DLBCL was primary CNS disease – 22 (25.0%)
– Patient expired before treatment could be initiated – 8 
(9.1%)
• Determined compliance based on NCCN guidelines2 for 
first-line chemotherapy and workup procediures
16/16 (100%) 23/31 (74.2%) 19/28 (67.9%) 24/40 (60.0%)
Figure 1.3-Year Survival Rate Breakdown by Clinical Stage at Diagnosis*
NCCN Treatment Guidelines Compliance*
Stages at Dx Compliant Patients Total Patients
Total % 
Compliance
I & II 61 67 91.0%
III & IV 84 93 90.3%
NCCN Workup Guidelines Compliance*
IPI Score Compliant Patients Total Patients
Total % 
Compliance
Included 27 181 14.9%
Omitted 128 181 70.7%
Survival Rate Comparison
Source Time-Scale
Total % Per Stage at Dx
I II III IV Overall
LVHN* 3-years 100% 74.2% 67.9% 60.0% 72.4%
NCI SEER3 5-years 73.3% 72.7% 63.7% 52.7% 63.8%
*Compliance = Documented LDH, ECOG, ± B Symptoms, PET Scan, Hepatitis B test, ECHO/MUGA [+anthracycline] 
*Compliance = First treatment modality followed NCCN flowchart 3 for selection based on stage group at diagnosis
• Comparison to SEER statistics:
– LVHN’s 3-year survival rates exceed all corresponding 5-
year metrics provided by SEER
– DLBCL outcomes are at or exceeding national average
• Though, direct comparison is difficult due to different 
time-scales
• NCCN workup:
– Found a general absence of documented IPI scores
• Led to a low overall workup compliance (14.9%)
• However, IPI is a prognostic index and doesn’t have 
large impact on care plan
– When omitted, 70.7% of workups are compliant
• NCCN treatment:
– Overall treatment compliance was 145/150 (90.6%)
• Deviations from compliance can be explained case-to-
case
• Overall:
– LVHN is compliant with NCCN guidelines and provides a 
high standard of care for its DLBCL patients.
• In 2 years, recalculate survival rates per stage to have direct 
comparison to 5-year SEER statistics
• Emphasize better documentation of IPI score in EMR
– IPI scores have been documented as general prognostic 
statements such as “high risk”
• Can be converted to numerical score, however nothing 
differentiates these statements from a general prognosis  
– NCCN occasionally uses IPI to select chemotherapy regimen














Figure 2.NCCN Workup Compliance By Year (IPI Score Omitted)
*Calculations in Table 1. and Figure 1. omit patients from 2018 that are not yet 3 years out from diagnosis.
